<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why is rxrx down today
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        6/27/2024 08:16am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Recursion Pharmaceuticals' stock decline today can be attributed to several factors:

1. **Earnings Report**: The company is projected to report earnings of -$0.41 per share, which would represent a year-over-year decline of 7.89%. This anticipated decline in earnings could contribute to the negative sentiment around the stock.
2. **Revenue Concerns**: The consensus estimate forecasts revenue to be $15.98 million, indicating a 45.01% growth compared to the corresponding quarter of the prior year. While revenue growth is positive, the absolute revenue figure may not meet market expectations, leading to a sell-off.
3. **Market Sentiment**: The broader market sentiment towards biotechnology stocks may also play a role. If there is a general downturn in the biotech sector or concerns about the industry's performance, it could impact Recursion Pharmaceuticals' stock price negatively.

In conclusion, the drop in RXRX's stock price today is likely a combination of investor reactions to the company's upcoming earnings report, revenue expectations, and overall market sentiment towards biotechnology stocks.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K){return {layout:"default",data:[{noData:g,currentQuestion:c,textDescription:u,comeFrom:"AInvestShareLink",events:h,answerSource:k}],fetch:{},error:h,state:{sharePreviewModule:{loadJgySuccess:v,dialogRenderList:[{originAnswer:{input_media_info:[],bottom_reason:{chain_name:a,reason_msg:a,bottom_type:a,bottom_level:a},agent_id:a,output_media_info:[],task_id:a,source:k,execute_mode:w,param:"{\"trace_id\":\"20003020171944737899000000000140\",\"question\":\"Why is rxrx down today\",\"user_id\":\"1801842011\",\"user_name\":\"\",\"input_type\":\"typewrite\",\"session_id\":\"72fd1d11a12070ce6531c9ce52966085\",\"source\":\"ths_wencai_international\"}",agent_info:[{info_type:x,title:y,full_summary:"You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion\u002Frating\u002Freport or any approach to evaluating individual securities. If you wish to go to ZacksTrade, click OK. If you do not, click Cancel. OK Cancel The most recent trading session ended with Recursion Pharmaceuticals (RXRX Quick QuoteRXRX - Free Report) standing at $9.38, reflecting a +0.43% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%. The biotechnology company's shares have seen an increase of 1.97% over the last month, not keeping up with the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83%. The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. On that day, Recursion Pharmaceuticals is projected to report earnings of -$0.41 per share, which would represent a year-over-year decline of 7.89%. In the meantime, our current consensus estimate forecasts the revenue to be $15.98 million, indicating a 45.01% growth compared to the corresponding quarter of the prior year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.60 per share and revenue of",summary:a,url:z,publish_time:"2024-06-25"},{info_type:x,title:A,full_summary:"Loading... Loading... Recursion Pharmaceuticals's RXRX short percent of float has risen 4.63% since its last report. The company recently reported that it has 42.37 million shares sold short, which is 26.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.19 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish. See Also: List of the most shorted stocks Loading... Loading... Recursion Pharmaceuticals Short Interest Graph (3 Months) As you can see from the chart above the percentage of shares that are sold short for Recursion Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted. Comparing Recursion Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is an",summary:a,url:B,publish_time:"2024-05-30"}],answer_chain_name:"agent_common_v2\nagent-summary",come_from:a,text_answer:u,trace_id:n,cost:26098,question:c,input_type:C,session_id:o,first_return_cost:818,transfer_question:c,start_time:D,remote_svc:"jgateway",slots:[],intervene_result:[],answer_type:w,user_id:l,skill_name:E},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",base_info:{trace_id:n,session_id:o,user_id:l,question:c,source:k,raw_question:c,version:"3.3.2"},extra:{}},{answer_path:d,section:{id:e,info_texts:["Thinking"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},extra:{}},{answer_path:d,section:{id:e,info_texts:["Searching Web : Recursion down reason"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:m},extra:{}},{answer_path:d,section:{id:e,info_texts:["Reading News : RXRX"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:m},extra:{}},{answer_path:d,section:{id:e,info_texts:["Querying Stock : RXRX industry"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:m},extra:{}},{answer_path:d,section:{id:e,info_texts:["Searching Web : Biotechnology growth"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:m},extra:{}},{answer_path:d,section:{id:e,info_texts:["Generating Answer"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},extra:{}},{answer_path:i,section:{id:p,info_texts:[],show_type:j,voice_txt:"Rec",text_answer:F,rich_text:F,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:i,section:{id:G,info_texts:[],show_type:j,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:z,title:y,summary:a,index:6}],is_last:b},extra:{}},{answer_path:i,section:{id:p,info_texts:[],show_type:j,voice_txt:a,text_answer:H,rich_text:H,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:i,section:{id:G,info_texts:[],show_type:j,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:B,title:A,summary:a,index:10}],is_last:b},extra:{}},{answer_path:i,section:{id:p,info_texts:[],show_type:j,voice_txt:"[^10]",text_answer:I,rich_text:I,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:d,section:{id:e,info_texts:["Completed"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:J,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10001,info_texts:[],show_type:J,choice:[{display_text:q,query_text:q,trace_info:{item_id:"d001dd3f695fad3fa7cebb0e6e0969da",item_type:r,item_name:q,rec_info:"0+320_350_21_130+0+0+20003020171944737899000000000140+d001dd3f695fad3fa7cebb0e6e0969da+llm_generated+aimeTagOther+0+primary+1"}},{display_text:s,query_text:s,trace_info:{item_id:"88d1ee42a1577a6753263ae6824b4d53",item_type:r,item_name:s,rec_info:"0+320_350_21_130+0+0+20003020171944737899000000000140+88d1ee42a1577a6753263ae6824b4d53+llm_generated+aimeTagOther+0+primary+2"}},{display_text:t,query_text:t,trace_info:{item_id:"99095ac4583439726a4a96933e42fa58",item_type:r,item_name:t,rec_info:"0+320_350_21_130+0+0+20003020171944737899000000000140+99095ac4583439726a4a96933e42fa58+llm_generated+aimeTagOther+0+primary+3"}}],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:"signal",choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{action_name:E,link_ids:[],with_paid_index:g},is_last:b}],questionItem:{data:{qStr:c,encodeFlag:g,imageData:h,docsData:[],quoteData:h},tplType:"question"},events:void 0,agentId:a,param:{trace_id:n,question:c,user_id:l,user_name:a,input_type:C,session_id:o,source:k}}],userId:l,userName:a,startTime:D,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:h,endSignal:g,theme:"white",showTracePopup:g,traceListData:[],chatTraceTargetIndex:v,traceTableData:h,showMask:g}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-is-rxrx-down-today-70749c\u002F",config:{_app:{basePath:K,assetsPath:K,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,"Why is rxrx down today","progress\u002Fsearching_for",1000,"searching_for",false,null,"other\u002FopenAnswer","rich_text","ths_wencai_international","1801842011","thinking","20003020171944737899000000000140","72fd1d11a12070ce6531c9ce52966085",2001,"What are the recent earnings reports for rxrx and how do they compare to analyst expectations?","llm_generated","What is the current market sentiment and investor expectations for rxrx?","How has the stock price of rxrx performed over the past year and what factors have influenced its movement?","Recursion Pharmaceuticals' stock decline today can be attributed to several factors:\n\n1. **Earnings Report**: The company is projected to report earnings of -$0.41 per share, which would represent a year-over-year decline of 7.89%. This anticipated decline in earnings could contribute to the negative sentiment around the stock.\n2. **Revenue Concerns**: The consensus estimate forecasts revenue to be $15.98 million, indicating a 45.01% growth compared to the corresponding quarter of the prior year. While revenue growth is positive, the absolute revenue figure may not meet market expectations, leading to a sell-off.\n3. **Market Sentiment**: The broader market sentiment towards biotechnology stocks may also play a role. If there is a general downturn in the biotech sector or concerns about the industry's performance, it could impact Recursion Pharmaceuticals' stock price negatively.\n\nIn conclusion, the drop in RXRX's stock price today is likely a combination of investor reactions to the company's upcoming earnings report, revenue expectations, and overall market sentiment towards biotechnology stocks.",0,"agent","search","Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing","https:\u002F\u002Fwww.zacks.com\u002Fstock\u002Fnews\u002F2293188\u002Frecursion-pharmaceuticals-rxrx-surpasses-market-returns-some-facts-worth-knowing","How Is The Market Feeling About Recursion Pharmaceuticals?","https:\u002F\u002Fwww.benzinga.com\u002Finsights\u002Fshort-sellers\u002F24\u002F05\u002F39087701\u002Fhow-is-the-market-feeling-about-recursion-pharmaceuticals","typewrite",1719447379011,"explain market events","Recursion Pharmaceuticals' stock decline today can be attributed to several factors:\n\n1. **Earnings Report**: The company is projected to report earnings of -$0.41 per share, which would represent a year-over-year decline of 7.89%. This anticipated decline in earnings could contribute to the negative sentiment around the stock",2000,"[^6].\n2. **Revenue Concerns**: The consensus estimate forecasts revenue to be $15.98 million, indicating a 45.01% growth compared to the corresponding quarter of the prior year. While revenue growth is positive, the absolute revenue figure may not meet market expectations, leading to a sell-off[^6].\n3. **Market Sentiment**: The broader market sentiment towards biotechnology stocks may also play a role. If there is a general downturn in the biotech sector or concerns about the industry's performance, it could impact Recursion Pharmaceuticals' stock price negatively","[^10].\n\nIn conclusion, the drop in RXRX's stock price today is likely a combination of investor reactions to the company's upcoming earnings report, revenue expectations, and overall market sentiment towards biotechnology stocks.","choice","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>